Percutaneous Valve Interventions in Heart Failure

AbstractPurpose of reviewHeart failure remains a major cause of morbidity and mortality despite advances in guideline directed medical and electrophysiologic device therapies. Valvular heart disease (VHD) is common in heart failure patients and independently associated with poor outcomes. This review provides an update in the rapidly evolving field of transcatheter heart valve interventions (THVI) in the management of heart failure.Recent findingsAortic stenosis (AS) may cause or worsen heart failure. Functional mitral regurgitation (FMR) and functional tricuspid regurgitation (FTR) occur secondary to heart failure and contribute to ongoing adverse remodeling. Each of these valvular lesions is independently associated with worse clinical outcomes including mortality. Transcatheter aortic valve replacement (TAVR) has revolutionized the management of AS. Challenges unique to the mitral and tricuspid valves are being answered by a multitude of different device designs with promising early data, most notably for edge-to-edge leaflet repair.SummaryUnbridled innovation in THVI technologies stand to dramatically alter the management of VHD in heart failure patients. Here we will review the complex interactions between VHD and heart failure, appraise the data surrounding THVI devices, and discuss opportunities for future research.
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research

Related Links:

Abstract Ischemic heart disease is a predominant cause of death worldwide. The loss or death of cardiomyocytes due to restricted blood flow often results in a cardiac injury. These injured cardiomyocytes are replaced by myofibroblasts that preserve structural integrity. However, the depleted cardiomyocytes lead to cardiac dysfunction such as pathological cardiac dilation, reduced cardiac contraction and fibrosis. Repair and regeneration of myocardium are the best possible therapy for the end-stage heart failure patients because the current therapies that can help restore the lost cardiomyocytes are limited to hear...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
This study shows that CA are released from periventricular and subpial regions to the cerebrospinal fluid and are present in the cervical lymph nodes, into which cerebrospinal fluid drains through the meningeal lymphatic system. We also show that CA can be phagocytosed by macrophages. We conclude that CA can act as containers that remove waste products from the brain and may be involved in a mechanism that cleans the brain. Moreover, we postulate that CA may contribute in some autoimmune brain diseases, exporting brain substances that interact with the immune system, and hypothesize that CA may contain brain markers that m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Last month, Medtronic announced receipt of U.S. Food and Drug Administration (FDA) approval for and launch of the Evolut Pro+ TAVR (Transcatheter Aortic Valve Replacement) System to treat patients with symptomatic severe aortic stenosis. Aortic steno...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Cardiology Exclusive Source Type: blogs
Abstract Valvular heart diseases are one of the most frequent causes for heart failure. Degenerative diseases of the aortic and mitral valve as well as a dysfunctional tricuspid valve disease result in a worse clinical outcome if severe. Minimal-invasive, surgical and/or catheter-based structural heart disease (SHD) interventions have recently seen a dramatic increase. Transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS) is a disruptive technology, and next generation devices and careful patient selection will minimize limitations of TAVI such as paravalvular leak, conductance disturbance...
Source: Journal of Cardiology - Category: Cardiology Authors: Tags: J Cardiol Source Type: research
Echocardiography can help determine which patients with heart failure and leaking...Read more on AuntMinnie.comRelated Reading: Lung ultrasound beats chest x-ray for heart failure detection Societies renew call to pull ultrasound contrast warning ACC, ASE release echocardiography training guidance ASE offers TEE guidelines for congenital heart disease Heart valve-tracking algorithm boosts viability of 4D MRI
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Edwards Lifesciences (NYSE:EW) said today that it made a pair of strategic bets on the structural heart space, paying $35 million for the right to acquire Corvia Medical and paying an unspecified amount for some of mitral valve repair device maker Mitralign‘s assets. Tewksbury, Mass.-based Corvia is developing an interatrial shunt to treat heart failure by creating a small opening between the left and right atria to lower blood pressure in the left atrium and lungs. The device has CE Mark approval in the European Union and a pivotal U.S trial aimed at winning a nod from the FDA is under way, Edwards said. &ldquo...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Implants Featured Mergers & Acquisitions Replacement Heart Valves Edwards Lifesciences Source Type: news
CONCLUSIONS: An elevated RDW is associated with a worse outcome following valve surgery. The predictive ability of the RDW, when assessed by the area under the ROC curve, improved the predictive ability of the EuroSCORE II calculator. PMID: 30207123 [PubMed - in process]
Source: Journal of Heart Valve Disease - Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Congenital heart disease is the most common birth defect globally, affecting almost nine in every 1,000 babies. Tissue engineering, which involves combining regenerative cells, proteins, or drugs with biomaterials, is a promising strategy to treat co...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Exclusive Materials Source Type: blogs
Authors: Mizutani Y, Tada N, Masuda T, Hata M Abstract Coarctation of the aorta (CoA) is a relatively common congenital heart anomaly, and bicuspid aortic valve (BAV) is a common congenital heart disease that coexists with CoA. In larger children and adults with CoA, transcatheter intervention has gained acceptance, but for surgical high-risk patients with aortic stenosis, the use of transcatheter aortic valve implantation (TAVI) has been established. Recently, although favorable data have been reported for TAVI when treating BAV, simultaneous transcatheter intervention for CoA and BAV will prove to be a challenge ...
Source: Journal of Heart Valve Disease - Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Time limit: 0 Quiz-summary 0 of 20 questions completed Questions: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Information This test series requires login for attempting. You can login easily with your Facebook account (Use the CONNECT WITH icon on the upper part of right sidebar displaying t...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: General Cardiology Source Type: blogs
More News: Cardiology | Cardiovascular | Gastroschisis Repair | Heart | Heart Disease | Heart Failure | Heart Valve Disease | Heart Valve Surgery | Heart Valves